The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...

Shares have been on the move with the stock up 5.8% over the past month. The stock hit a new 52-week high of $58.22 in the previous session. Vertex has gained 6.2% since the start of the year compared ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

Vertex specializes in corporate tax compliance software, targeting a $22B global TAM with a focus on enterprise and SMB ...

The U.S. Bankruptcy Court for the Southern District of Texas allowed the company to exit bankruptcy as a privately-held company under the ownership of lenders. Those lenders include funds managed by ...

Vertex Energy has emerged as a privately held company after emerging from Chapter 11 bankruptcy. The company company filed for protections in 2024 after spending on equipment ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...

This non-opioid pain drug targets a multibillion-dollar market. Vertex also has multiple other catalysts on the way in 2025 ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

The polar vortex, a natural atmospheric phenomenon, influences global winter weather by circulating Arctic air. Its expansion ...